RPL35AP13

Across TCGA pan-cancer cohorts, RPL35AP13 RNA is linked to patient survival in 19 of 34 cancer types, making it the most broadly survival-associated RPL35AP13 data layer.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RPL35AP13 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL35AP13 expression acts as an unfavorable survival marker, although some lineages such as CHOL and PRAD show a favorable association.

OV, SKCM, and LGG are the cancer types where RPL35AP13 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Quartile	All	0.316	0.432	.007	72	view →
SKCM	DFS	Tertile	II,III,IV	0.583	0.728	.001	49	view →
LGG	DFS	Tertile	All	0.294	0.476	.001	26	view →
KICH	DFS	Quartile	All	0.411	1.000	<.001	25	view →
PAAD	OS	Median	All	0.217	0.424	.005	18	view →
CHOL	DFS	Tertile	All	1.000	0.306	.044	9	view →
ACC	DFS	Tertile	All	0.388	0.651	.010	8	view →
PRAD	DFS	Quartile	All	0.901	0.754	.012	8	view →
BRCA	DFS	Tertile	III,IV	0.941	0.824	.011	7	view →
COAD	DFS	Median	III,IV	0.227	0.509	.007	6	view →
UCS	DFS	Median	IV	0.885	0.440	.015	6	view →
LUSC	DFS	Median	II,III,IV	0.656	0.773	.014	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 19 lineages.

RPL35AP13–OV (DFS)

Open the OV breakdown →